VT30 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
278	巨大リンパ管奇形（頚部顔面病変）	1
279	巨大静脈奇形（頚部口腔咽頭びまん性病変）	1

278. 巨大リンパ管奇形（頚部顔面病変）

---

臨床試験数 : 22 /  薬物数 : 27 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04409145 (ClinicalTrials.gov)	October 1, 2020	11/5/2020	First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations	Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations	Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation	Drug: VT30	Venthera, Inc., a BridgeBio company	NULL	Recruiting	18 Years	60 Years	All	51	Phase 1/Phase 2	United States

279. 巨大静脈奇形（頚部口腔咽頭びまん性病変）

---

臨床試験数 : 14 /  薬物数 : 24 - (DrugBank : 9) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04409145 (ClinicalTrials.gov)	October 1, 2020	11/5/2020	First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations	Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations	Venous Malformation;Lymphatic Malformation;Venolymphatic Malformation	Drug: VT30	Venthera, Inc., a BridgeBio company	NULL	Recruiting	18 Years	60 Years	All	51	Phase 1/Phase 2	United States